SCHEMBL13547720

SCHEMBL13547720

COC(C)CN1CCN(C)CC1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.43
MAPT P10636 2/20 0.43
TSHR P16473 2/20 0.43
ALDH1A1 P00352 3/20 0.42
CYP2D6 P10635 1/20 0.42
USP2 O75604 1/20 0.42
KDM4E B2RXH2 2/20 0.41
GLA P06280 1/20 0.41
RAB9A P51151 1/20 0.40
GAA P10253 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.36
DRD2 P14416 1/20 0.34
DRD3 P35462 1/20 0.34
LMNA P02545 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13132269 0.81 MEN1 (0.42) POLBSMN1; SMN2MAPTTSHRUSP2
SCHEMBL14435203 0.81 MEN1 (0.42) POLBSMN1; SMN2MAPTTSHRUSP2
SCHEMBL6511981 0.81 MEN1 (0.42) POLBSMN1; SMN2MAPTTSHRUSP2
SCHEMBL24091780 0.80 POLB (0.44) POLBSMN1; SMN2MAPTTSHRALDH1A1
SCHEMBL18390141 0.80 DRD2 (0.33) POLBSMN1; SMN2ALDH1A1CYP2D6KDM4E
SCHEMBL20349515 0.80 DRD2 (0.33) POLBSMN1; SMN2ALDH1A1CYP2D6DRD2
SCHEMBL13547722 0.79 MEN1 (0.46) POLBSMN1; SMN2TSHRUSP2L3MBTL1
SCHEMBL23205839 0.79 MEN1 (0.46) POLBSMN1; SMN2TSHRUSP2L3MBTL1
SCHEMBL27429921 0.79 KDM4E (0.42) POLBSMN1; SMN2MAPTTSHRALDH1A1
SCHEMBL18713224 0.78 KDM4E (0.39) POLBSMN1; SMN2MAPTTSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3689868-B1 TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS ARVINAS OPERATIONS INC (US) 2023-09-27 EP disclosed
US-10023570-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2018-07-17 US disclosed
US-20170096425-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA, INC. 2017-04-06 US disclosed
US-7652051-B2 Heterocyclic compounds and methods of use TARGEGEN, INC. (US) 2010-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170096425-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF POLB 3474/4885SMN1; SMN2 989/4885MAPT 2183/4885
US-10023570-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF POLB 3474/4885SMN1; SMN2 989/4885MAPT 2183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.